New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
06:56 EDTACHNAchillion reports interim results on ACH-3102
Achillion announced that it has completed enrollment in a pilot Phase 2a trial evaluating ACH-3102, a second-generation pan-genotypic NS5A inhibitor, in combination with ribavirin for the treatment of patients with chronic genotype 1b hepatitis C virus infection. Up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic breakthrough observed to date.
News For ACHN From The Last 14 Days
Check below for free stories on ACHN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACHN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use